Robert M. Grotzfeld

A small molecule–kinase interaction map for clinical kinase inhibitors

Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text

Molecular Docking, Drug Target, Clinical Kinase Inhibitors +4

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

Todd A. Carter, Lisa Wodicka, Neil P. Shah et al. · Proceedings of the National Academy of Sciences · 2005 · 554 citations · Full text

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

Identification of <i>N</i>-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor

Qi Chao, Kelly G. Sprankle, Robert M. Grotzfeld et al. · Journal of Medicinal Chemistry · 2009 · 189 citations · Full text

Drug Target, Aml Patients, Pharmacotherapy +20

Control of Self-Assembly and Reversible Encapsulation of Xenon in a Self-Assembling Dimer by Acid-Base Chemistry

Neil R. Branda, Robert M. Grotzfeld, Carlos Valdés et al. · Journal of the American Chemical Society · 1995 · 154 citations

Supramolecular Assembly, Engineering, Acid-base Chemistry +18